*For medical professionals only
Clinical information, 1s reach
Chronic plus acute liver failure (ACLF) is a clinical syndrome in which acute decompensation of liver function occurs on the basis of chronic liver disease, often accompanied by multi-organ failure, and the short-term (28 days to 3 months) case fatality rate is extremely high [1].
The dangerous condition of ACLF and the complex pathophysiology of ACLF can partially reverse liver function after the removal of triggers and effective treatment, but many patients with severe disease can only rely on liver transplantation or in vitro liver replacement therapy to survive [1].
The World Gastroenterology Organization (WGO) believes that infection and sepsis can be acute triggers for ACLF[1]. So, if the prophylactic use of the antibacterial drug norfloxacin can effectively prevent bacterial infections, remove one of the acute triggers of ACLF, and thus improve the transplant-free survival of ACLF patients?
Source: Screenshot of literature
Recently, Anand V Kulkarni et al. published a paper in the Am J Gastroenterol that showed that initial use of norfloxacin was effective in preventing bacterial infections in patients with ACLF [2]. Let's take a look at today's newsletter!
Want to see more of the previous issues of "Top Essentials"?
Go to the "Clinical Decision Assistant" service number to see!